Novalpina Capital completed the acquisition of Laboratoire X.O.

Private equity firm Novalpina Capital completed the acquisition of Laboratoire X.O, the French specialty pharmaceuticals business. Financial terms were not disclosed. "Starting from small beginnings in 2015, I am proud to have grown X.O into a fast-growing niche-player in branded pharmaceuticals. With our strong base in the French market, we see tremendous opportunity for continued growth both in France and internationally. I am impressed by Novalpina Capital’s vision for the business, and I am pleased to continue in partnership with both them and X.O’s excellent management team, as a Board member and investor," Gerard Leduc, Laboratoire X.O Founder.